Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547677 | 0.90 | PPARD (0.44) | PTPN1PTPN2PTPN6PTPRCPTPRB | |
| SCHEMBL13443139 | 0.88 | CARM1 (0.50) | RXRARXRBRXRGHTR1ADRD2 | |
| SCHEMBL13443113 | 0.82 | HTR1A (0.59) | HTR1ADRD2ABCB1 | |
| SCHEMBL2290382 | 0.80 | PTPN1 (0.54) | PTPN1PTPN2PTPN6PTPRCPTPRB | |
| SCHEMBL13443160 | 0.79 | HTR1A (0.47) | HTR1ADRD2ABCB1 | |
| SCHEMBL12384421 | 0.78 | IDO1 (0.47) | PTPN1RXRARXRBRXRGHTR1A | |
| Bromide SCHEMBL2290372 | 0.77 | PTPN1 (0.47) | PTPN1PTPN2PTPN6PTPRCPTPRB | |
| SCHEMBL12384370 | 0.76 | PTPN1 (0.43) | PTPN1PPARD | |
| SCHEMBL5511945 | 0.76 | PTPRC (0.54) | PTPN1PTPN2PTPN6PTPRCPTPRB | |
| SCHEMBL3457914 | 0.76 | PTPRC (0.54) | PTPN1PTPN2PTPN6PTPRCPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | PTPN1 3484/4885PTPN2 3313/4885PTPN6 3537/4885 |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | PC, SLC25A1, GOT2 | PTPN1 4670/4885PTPN2 4471/4885PTPN6 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.